Roche announces European approval of Venclyxto for people with hard-to-treat chronic lymphocytic leukaemia

Roche announced today that the European Commission has granted conditional marketing approval for Venclyxto ™ (venetoclax) for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in people who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of CLL without 17p deletion or TP53 mutation in people who have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news